Breast Cancer Heterogeneity and Response to Novel Therapeutics

Baliu-Piqué, Mariona; Pandiella, Atanasio; Ocaña, Alberto

doi:10.3390/cancers12113271

Cited by 51 publications

(49 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decades of research on cancer biology have revealed that tumors are heterogeneous entities at all scales (macroscopic, physiological, microscopic and genetic) [ 1 , 2 , 3 , 4 ], with different regions showing distinct morphological and phenotypic profiles [ 5 , 6 , 7 ]. Nowadays, it is widely accepted that tumor heterogeneity has profound implications in tumor development, therapeutic outcomes and survival [ 8 , 9 , 10 , 11 ], making it essential to develop methods for studying tumor heterogeneity in vivo [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Although many works have supported the utility of PET radiomics, several authors have raised concerns over the robustness and replicability of the results. This study aimed to perform a systematic review on the topic of PET radiomics and the used methodologies. Methods: PubMed was searched up to 15 October 2020. Original research articles based on human data specifying at least one tumor type and PET image were included, excluding those that apply only first-order statistics and those including fewer than 20 patients. Each publication, cancer type, objective and several methodological parameters (number of patients and features, validation approach, among other things) were extracted. Results: A total of 290 studies were included. Lung (28%) and head and neck (24%) were the most studied cancers. The most common objective was prognosis/treatment response (46%), followed by diagnosis/staging (21%), tumor characterization (18%) and technical evaluations (15%). The average number of patients included was 114 (median = 71; range 20–1419), and the average number of high-order features calculated per study was 31 (median = 26, range 1–286). Conclusions: PET radiomics is a promising field, but the number of patients in most publications is insufficient, and very few papers perform in-depth validations. The role of standardization initiatives will be crucial in the upcoming years.

show abstract

Section: Introductionmentioning

confidence: 99%

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Breast cancer is a heterogeneous disease that differs greatly not only among patients, but also within each individual tumor, which may explain the variability regarding therapeutic responses and disease progression ( Coates et al, 2015 ; Baliu-Pique et al, 2020 ). 3D organotypic models represent powerful tools to replicate such heterogeneity, including tumor-stroma interactions, being central for comprehending cancer-related mechanisms and drug response.…”

Section: Introductionmentioning

confidence: 99%

Engineering a Vascularized 3D Hybrid System to Model Tumor-Stroma Interactions in Breast Cancer

Teixeira

Chaves

Torres

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The stromal microenvironment of breast tumors, namely the vasculature, has a key role in tumor development and metastatic spread. Tumor angiogenesis is a coordinated process, requiring the cooperation of cancer cells, stromal cells, such as fibroblasts and endothelial cells, secreted factors and the extracellular matrix (ECM). In vitro models capable of capturing such complex environment are still scarce, but are pivotal to improve success rates in drug development and screening. To address this challenge, we developed a hybrid alginate-based 3D system, combining hydrogel-embedded mammary epithelial cells (parenchymal compartment) with a porous scaffold co-seeded with fibroblasts and endothelial cells (vascularized stromal compartment). For the stromal compartment, we used porous alginate scaffolds produced by freeze-drying with particle leaching, a simple, low-cost and non-toxic approach that provided storable ready-to-use scaffolds fitting the wells of standard 96-well plates. Co-seeded endothelial cells and fibroblasts were able to adhere to the surface, spread and organize into tubular-like structures. For the parenchymal compartment, a designed alginate gel precursor solution load with mammary epithelial cells was added to the pores of pre-vascularized scaffolds, forming a hydrogel in situ by ionic crosslinking. The 3D hybrid system supports epithelial morphogenesis in organoids/tumoroids and endothelial tubulogenesis, allowing heterotypic cell-cell and cell-ECM interactions, while presenting excellent experimental tractability for whole-mount confocal microscopy, histology and mild cell recovery for down-stream analysis. It thus provides a unique 3D in vitro platform to dissect epithelial-stromal interactions and tumor angiogenesis, which may assist in the development of selective and more effective anticancer therapies.

show abstract

“…1 BC has profound genetic heterogeneity and tumor heterogeneity, which is closely associated with poor prognosis and survival, leading determinants of therapeutic resistance and treatment failure. 2,3 Therefore, an accurate assessment of tumor pharmacological heterogeneity is required for the development of effective therapies. A great number of studies have been done using cancer cell lines and patient-derived xenografts, which include different advantages.…”

mentioning

confidence: 99%

Optimizing individualized treatment strategy based on breast cancer organoid model

Pan

Zhao

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

Pharmacological characteristics of PDTOs derived from different BC patients. (A) Drug dose-response curves of PDTOs from different molecular types of BC patients for Tamoxifen, Fulvestrant, Paclitaxel, Docetaxel, Cyclophosphamide, Epirubicin, Carboplatin, Palbociclib. Mean ± SD of results from three independent experiments is shown for each drug. (B) Drug dose-response curves of multifocal BC PDTOs for Tamoxifen, Fulvestrant, Paclitaxel, Docetaxel, Cyclophosphamide, Epirubicin, Carboplatin, and Palbociclib. Mean ± SD of results from three independent experiments is shown for each drug. (C) Drug dose-response curves of bilateral BC PDTOs for Tamoxifen, Fulvestrant, Paclitaxel, Docetaxel, Cyclophosphamide, Epirubicin, Carboplatin, and Palbociclib. Mean ± SD of results from three independent experiments is shown for each drug. (D) Drug dose-response curves of neoadjuvant BC PDTOs for Docetaxel, Cyclophosphamide, and Epirubicin. Mean ± SD of results from three independent experiments is shown for each drug. Bright-field microscopy images of neoadjuvant BC PDTOs were treated with indicated drugs. Scale bars, 200 μm. CTX: Cyclophosphamide. (E) Drug dose-response curves of neoadjuvant BC PDTOs for Tamoxifen, Fulvestrant, Paclitaxel, Palbociclib, and Carboplatin. Mean ± SD of results from three independent experiments is shown for each drug. Bright-field microscopy images of neoadjuvant BC PDTOs were treated with indicated drugs. Scale bars, 200 μm

show abstract

Breast Cancer Heterogeneity and Response to Novel Therapeutics

Cited by 51 publications

References 141 publications

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

A Systematic Review of PET Textural Analysis and Radiomics in Cancer

Engineering a Vascularized 3D Hybrid System to Model Tumor-Stroma Interactions in Breast Cancer

Optimizing individualized treatment strategy based on breast cancer organoid model

Contact Info

Product

Resources

About